Expression of cell cycle regulator p27Kip1 is correlated with survival of patients with astrocytoma.

p27Kip1 is a cyclin-dependent kinase inhibitor that negatively regulates cell proliferation by mediating cell cycle arrest in G1. This study was undertaken to assess the prognostic value of p27Kip1 for astrocytomas. Tissue samples from 130 astrocytomas (WHO grade 1, 5 cases; grade 2, 23 cases; grade 3, 64 cases; grade 4, 38 cases), including 92 primary and 38 recurrent tumors, were examined immunohistochemically for Ki-67 and p27Kip1 expression. Patient charts were reviewed for clinical presentation, and survival was followed. The p27Kip1 labeling index (LI) ranged from 2.3 to 98.4%, with a mean value of 47.5% (+/-23.4%). The p27Kip1 LI decreased with increasing tumor grade but did not correlate with other parameters. There was no correlation between Ki-67 LI and p27Kip1 LI. For patients with primary astrocytomas, the 50% survival times of those with low p27Kip1 LI (<50%) and those with high p27Kip1 LI (> or =50%) were 17.1 and 69.6 months, respectively. For patients with high-grade tumors, the 50% survival times were 13.1 months for those with low p27Kip1 LI and 33.7 months for those with high LI. On multivariate analysis, p27Kip1 was one of the most significant prognostic factors, indicating that low p27Kip1 LI was associated with poor prognosis (primary, risk ratio = 2.5, P = 0.0023; high-grade, risk ratio = 2.2; P = 0.0139). The expression of p27Kip1 was inversely related to tumor grade and positively related to favorable outcome of patients with astrocytoma, suggesting that p27Kip1 may be a candidate for prognostic factor for this tumor.

[1]  L. Klotz,et al.  Loss of cyclin-dependent kinase inhibitor p27Kip1 is a novel prognostic factor in localized human prostate adenocarcinoma. , 1998, Cancer research.

[2]  D. Schiffer,et al.  p27/kip1 expression in human astrocytic gliomas , 1997, Neuroscience Letters.

[3]  Esposito,et al.  Prognostic role of the cyclin-dependent kinase inhibitor p27 in non-small cell lung cancer. , 1997, Cancer research.

[4]  K. Mimori,et al.  p27 expression and gastric carcinoma , 1997, Nature Medicine.

[5]  D. Louis,et al.  Accumulation of wild-type p53 in astrocytomas is associated with increased p21 expression , 1997, Acta Neuropathologica.

[6]  M. Loda,et al.  The cell cycle inhibitor p27 is an independent prognostic marker in small (T1a,b) invasive breast carcinomas. , 1997, Cancer research.

[7]  M. Loda,et al.  Increased proteasome-dependent degradation of the cyclin-dependent kinase inhibitor p27 in aggressive colorectal carcinomas , 1997, Nature Medicine.

[8]  Herman Yeger,et al.  Decreased levels of the cell-cycle inhibitor p27Kip1 protein: Prognostic implications in primary breast cancer , 1997, Nature Medicine.

[9]  James M. Roberts,et al.  Expression of cell-cycle regulators p27Kip1 and cyclin E, alone and in combination, correlate with survival in young breast cancer patients , 1997, Nature Medicine.

[10]  K. Kunishio,et al.  Malignant astrocytomas with homozygous CDKN2/p16 gene deletions have higher Ki-67 proliferation indices. , 1996, Journal of neuropathology and experimental neurology.

[11]  K. Manova-Todorova,et al.  Enhanced Growth of Mice Lacking the Cyclin-Dependent Kinase Inhibitor Function of p27 Kip1 , 1996, Cell.

[12]  Nobuyuki Shishido,et al.  Mice Lacking p27 Kip1 Display Increased Body Size, Multiple Organ Hyperplasia, Retinal Dysplasia, and Pituitary Tumors , 1996, Cell.

[13]  James M. Roberts,et al.  A Syndrome of Multiorgan Hyperplasia with Features of Gigantism, Tumorigenesis, and Female Sterility in p27 Kip1 -Deficient Mice , 1996, Cell.

[14]  K. Kidd,et al.  The world-wide distribution of allele frequencies at the human dopamine D4 receptor locus , 1996, Human Genetics.

[15]  James M. Roberts,et al.  Requirement of p27Kip1 for Restriction Point Control of the Fibroblast Cell Cycle , 1996, Science.

[16]  L. Hengst,et al.  Translational Control of p27Kip1 Accumulation During the Cell Cycle , 1996, Science.

[17]  P. Beer-Romero,et al.  Role of the ubiquitin-proteasome pathway in regulating abundance of the cyclin-dependent kinase inhibitor p27. , 1995, Science.

[18]  C. Bartram,et al.  Molecular analysis of the cyclin-dependent kinase inhibitor gene p27/Kip1 in human malignancies. , 1995, Cancer research.

[19]  James M. Roberts,et al.  Assignment of the human p27Kip1 gene to 12p13 and its analysis in leukemias. , 1995, Cancer research.

[20]  J. Massagué,et al.  p27Kip1: chromosomal mapping to 12p12-12p13.1 and absence of mutations in human tumors. , 1995, Cancer research.

[21]  James M. Roberts,et al.  lnterleukin-2-mediated elimination of the p27Kipl cyclin-dependent kinase inhibitor prevented by rapamycin , 1994, Nature.

[22]  T. Visakorpi,et al.  Prognostication of astrocytoma patient survival by Ki‐67 (MIB‐1), PCNA, and S‐phase fraction using archival paraffin‐embedded samples , 1994, The Journal of pathology.

[23]  T. Hunter,et al.  Cyclins and cancer II: Cyclin D and CDK inhibitors come of age , 1994, Cell.

[24]  C. Sherr.  G1 phase progression: Cycling on cue , 1994, Cell.

[25]  Charles B. Wilson,et al.  Correlation between the bromodeoxyuridine labeling index and the MIB‐1 and Ki‐67 proliferating cell indices in cerebral gliomas , 1994, Cancer.

[26]  Ludger Hengst,et al.  G1 control in mammalian cells , 1994, Journal of Cell Science.

[27]  R. Perry,et al.  Prognostic implications of p53 protein, epidermal growth factor receptor, and Ki-67 labelling in brain tumours. , 1992, British Journal of Cancer.

[28]  T. Hunter,et al.  Cyclins and cancer , 1991, Cell.

[29]  M. Prados,et al.  Prognostic implications of the bromodeoxyuridine labeling index of human gliomas. , 1989, Journal of neurosurgery.

[30]  M. Hamou,et al.  Identification of proliferating cells in human gliomas using the monoclonal antibody Ki-67. , 1988, Neurosurgery.

[31]  P J Kelly,et al.  A histologic and cytologic method for the spatial definition of gliomas. , 1987, Mayo Clinic proceedings.

[32]  S B Green,et al.  Patient age, histologic features, and length of survival in patients with glioblastoma multiforme , 1987, Cancer.

[33]  P. Burger,et al.  Malignant astrocytic neoplasms: classification, pathologic anatomy, and response to treatment. , 1986, Seminars in oncology.

[34]  S. Green,et al.  Glioblastoma multiforme and anaplastic astrocytoma pathologic criteria and prognostic implications , 1985, Cancer.

[35]  Johannes Gerdes,et al.  Production of a mouse monoclonal antibody reactive with a human nuclear antigen associated with cell proliferation , 1983, International journal of cancer.

[36]  H. Gratzner,et al.  Monoclonal antibody to 5-bromo- and 5-iododeoxyuridine: A new reagent for detection of DNA replication. , 1982, Science.

[37]  W. Shapiro.  Treatment of neuroectodermal brain tumors , 1982, Annals of neurology.

[38]  N. Mantel.  Evaluation of survival data and two new rank order statistics arising in its consideration. , 1966, Cancer chemotherapy reports.

[39]  E. Kaplan,et al.  Nonparametric Estimation from Incomplete Observations , 1958 .

[40]  B. Scheithauer,et al.  Analysis of proliferation markers and p53 expression in gliomas of astrocytic origin: relationships and prognostic value. , 1997, Journal of neurosurgery.

[41]  D. Louis,et al.  CDKN2/p16 or RB alterations occur in the majority of glioblastomas and are inversely correlated. , 1996, Cancer research.

[42]  D.,et al.  Regression Models and Life-Tables , 2022 .